Telix Pharmaceuticals and Regeneron Pharmaceuticals announced a collaboration to develop next-generation radiopharmaceutical therapies for solid tumors. Telix will receive $40 million upfront plus up to $2.1 billion in milestone payments and royalties. The partnership combines Telix's radiopharmaceutical platform with Regeneron's biologics expertise. Telix also reported Q1 revenue of $230 million (up 11% sequentially) and reaffirmed its 2026 guidance of $950-970 million. Additionally, the FDA accepted Telix's resubmitted application for Pixclara for brain cancer imaging.

The FDA has accepted Telix Pharmaceuticals' resubmitted New Drug Application for TLX101-Px1 (Pixclara), a PET imaging agent for glioma characterization, with a PDUFA goal date of September 11, 2026. The drug has received Orphan Drug and Fast Track designations and addresses a significant unmet medical need in distinguishing tumor progression from treatment-related changes in brain cancer patients.

Telix Pharmaceuticals announced the appointment of two experienced Non-Executive Directors effective May 11, 2026: Maria Rivas, MD, a former Pfizer Chief Medical Officer with 25+ years in pharmaceutical development, and William Jellison, a corporate finance leader with 30+ years experience and current board positions at Medtronic and other major companies. The appointments are part of the company's board expansion and succession planning as it evolves into a dual-listed, global, commercial-stage biopharmaceutical company.

Telix Pharmaceuticals reported Q1 2026 unaudited group revenue of US$230 million, up 11% quarter-over-quarter, with Precision Medicine revenue reaching US$186 million (up 16% QoQ). The company reaffirmed FY 2026 revenue guidance of US$950-970 million. Key highlights include successful completion of Part 1 of the ProstACT Global Phase 3 study for TLX591-Tx prostate cancer therapy, NDA resubmission for TLX101-Px brain cancer imaging candidate, and MAA filing in Europe. The company also announced the appointment of David Gill as Non-Executive Director.

Telix Pharmaceuticals announced the appointment of David Gill as Non-Executive Director effective May 11, 2026, with plans to appoint him as Chair succeeding Dr. Mark Nelson. Gill brings over 35 years of life sciences executive experience, including CFO and President roles at multiple publicly traded companies, and expertise in capital markets, business scaling, and governance.

Telix Pharmaceuticals has resubmitted a New Drug Application to the FDA for TLX101-Px (Pixclara), a PET imaging agent for characterizing recurrent or progressive glioma in adult and pediatric patients. The resubmission includes additional data requested by the FDA and addresses a Complete Response Letter. The drug has received Orphan Drug and Fast Track designations, with no FDA-approved targeted amino acid PET agent currently available in the U.S. market for brain cancer imaging.

Telix Pharmaceuticals announced that Part 1 of the ProstACT Global Phase 3 study for its therapeutic candidate TLX591-Tx (lutetium-177 rosopatamab tetraxetan) has achieved its primary objectives, demonstrating an acceptable safety and tolerability profile with no new safety signals. The study dosed 36 patients across three cohorts combining TLX591-Tx with standard of care therapies. The company is advancing to Part 2 and will present data to the FDA for an IND amendment to progress the trial in the U.S.

Telix Pharmaceuticals Limited announced a webinar scheduled for March 4-5, 2026, featuring key opinion leaders discussing innovations in PSMA-PET/CT imaging for prostate cancer. The event will include speakers from the University of Melbourne, UroPartners, and Telix leadership, moderated by the company's Chief Medical Officer.

Telix Pharmaceuticals, an Australian nuclear medicine company, is gaining attention for its cancer-targeting radiopharmaceuticals used for both detection and treatment. With 56% revenue growth in 2025, recent regulatory approvals for lead products Illuccix and Gozellix, and ownership of a 31-location radiopharmacy distribution network, analysts project the stock could triple from current levels. The company has multiple pipeline candidates in late-stage trials and a market cap of $2.3 billion.

Levi & Korsinsky announces a class action securities lawsuit against Telix Pharmaceuticals Ltd. for alleged securities fraud between February 21, 2025 and August 28, 2025. The complaint alleges the company made false statements about prostate cancer therapeutic progress, overstated supply chain quality, and made misleading statements about business operations. The lead plaintiff deadline is January 9, 2026.

Telix Pharmaceuticals announced that Managing Director and Group CEO Dr. Christian Behrenbruch will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026. The presentation will provide an overview of the company's pipeline assets and commercial portfolio, with a webcast available live and on-demand. Fourth quarter 2025 financials will be released on January 20, 2026.

Levi & Korsinsky has filed a class action securities lawsuit against Telix Pharmaceuticals Ltd. on behalf of investors who suffered losses between February 21, 2025 and August 28, 2025. The complaint alleges that defendants made false statements regarding prostate cancer therapeutic progress, overstated supply chain quality, and made materially misleading statements about the company's business and prospects. The deadline to request lead plaintiff status is January 9, 2026.